Compounds > 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Page last updated: 2024-09-03

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Prostatic Neoplasms, Castration-Resistant

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Prostatic Neoplasms, Castration-Resistant in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's4 (80.00)2.80

Authors

AuthorsStudies
Keam, SJ1
Jacene, H; Ravi, P; Shah, H; Sonpavde, G1
Agrawal, S; Amiri-Kordestani, L; Chen, W; Chiang, K; Fallah, J; Fiero, MH; Fotenos, A; Gittleman, H; Ibrahim, A; John, C; Kluetz, PG; Niu, G; Pazdur, R; Pierce, WF; Ricks, TK; Subramaniam, S; Suzman, DL; Tang, S; Wang, M1
Chen, ZS; Fang, GC; Han, CH; Liu, X; Lu, H; Shi, ZD1
Bander, NH; Goldsmith, SJ; Jhanwar, YS; Kaur, G; Nanus, DM; Nikolopoulou, A; Tagawa, ST; Vallabhajosula, S1

Reviews

4 review(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Prostatic Neoplasms, Castration-Resistant

ArticleYear
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Molecular diagnosis & therapy, 2022, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome

2022
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
    Expert review of anticancer therapy, 2022, Volume: 22, Issue:11

    Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2022
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
    Drugs of today (Barcelona, Spain : 1998), 2023, Volume: 59, Issue:1

    Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2023
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
    Current radiopharmaceuticals, 2016, Volume: 9, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antigens, Surface; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Male; Maximum Tolerated Dose; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Xenograft Model Antitumor Assays

2016

Trials

1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Prostatic Neoplasms, Castration-Resistant

ArticleYear
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 05-01, Volume: 29, Issue:9

    Topics: Adult; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Receptors, Androgen; Taxoids; Treatment Outcome

2023